Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma

Journal of the National Cancer Institute

Volumn 104, Issue 8, 2012, Pages 622-634

  Moldenhauer, Gerhard ^a   Salnikov, Alexei V ^a,b   Lüttgau, Sandra ^a   Herr, Ingrid ^b   Anderl, Jan ^c   Faulstich, Heinz ^d  

^a GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Wilex Biotechnology GmbH   (Germany)

^d MAX PLANCK INSTITUTE FOR MEDICAL RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA AMANITIN; EPITHELIAL CELL ADHESION MOLECULE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; THYMIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BILE DUCT CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CANCER REGRESSION; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; CROSS LINKING; DNA TRANSCRIPTION; DRUG CONJUGATION; FEMALE; IC 50; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PANCREAS CARCINOMA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SCID MOUSE; SINGLE DRUG DOSE; TUMOR VOLUME; TUMOR XENOGRAFT;

ALPHA-AMANITIN; ANGIOGENESIS INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL PROLIFERATION; CHIMERA; COLONIC NEOPLASMS; ENZYME INHIBITORS; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOCONJUGATES; IMMUNOHISTOCHEMISTRY; LIVER; MICE; MICE, INBRED NOD; MICE, SCID; PANCREATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84860142832     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djs140     Document Type: Article

References (55)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60(5):277-300.
2. Michalski CW, Weitz J, Buchler MW. Surgery insight: surgical management of pancreatic cancer. Nat Clin Pract Oncol. 2007;4(9):526-535. (Pubitemid 47351463)
3. Trzpis M, McLaughlin PM, de Leij LM, Harmsen MC. Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule. Am J Pathol. 2007;171(2):386-395. (Pubitemid 47344671)
4. Baeuerle PA, Gires O. EpCAM (CD326) finding its role in cancer. Br J Cancer. 2007;96(3):417-423. (Pubitemid 46215211)
5. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. The biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77(10):699-712.
6. Winter MJ, Nagtegaal ID, van Krieken JH, Litvinov SV. The epithelial cell adhesion molecule (Ep-CAM) as a morphoregulatory molecule is a tool in surgical pathology. Am J Pathol. 2003;163(6):2139-2148. (Pubitemid 37466457)
7. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Human Pathol. 2004;35(1):122-128. (Pubitemid 38133932)
8. Gastl G, Spizzo G, Obrist P, Dunser M, Mikuz G. Ep-CAM overexpression in breast cancer as a predictor of survival. Lancet. 2000;356(9246):1981-1982.
9. Varga M, Obrist P, Schneeberger S, et al. Overexpression of epithelial cell adhesion molecule antigen in gallbladder carcinoma is an independent marker for poor survival. Clin Cancer Res. 2004;10(9):3131-3136. (Pubitemid 38619694)
10. Spizzo G, Obrist P, Ensinger C, et al. Prognostic significance of Ep-CAM and Her-2/neu overexpression in invasive breast cancer. Int J Cancer. 2002;98(6):883-888. (Pubitemid 34286685)
11. Spizzo G, Went P, Dirnhofer S, et al. High Ep-CAM expression is associated with poor prognosis in node-positive breast cancer. Breast Cancer Res Treat. 2004;86(3):207-213. (Pubitemid 39070963)
12. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA. 2003;100(7):3983-3988. (Pubitemid 36418143)
13. Dalerba P, Dylla SJ, Park IK, et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci USA. 2007;104(24):10158-10163. (Pubitemid 47175279)
14. Li C, Heidt DG, Dalerba P, et al. Identification of pancreatic cancer stem cells. Cancer Res. 2007;67(3):1030-1037.
15. Armstrong A, Eck SL. EpCAM: a new therapeutic target for an old cancer antigen. Cancer Biol Ther. 2003;2(4):320-326.
16. Chaudry MA, Sales K, Ruf P, Lindhofer H, Winslet MC. EpCAM an immunotherapeutic target for gastrointestinal malignancy: current experience and future challenges. Br J Cancer. 2007;96(7):1013-1019. (Pubitemid 46608303)
17. Ammons WS, Bauer RJ, Horwitz AH, et al. In vitro and in vivo pharmacology and pharmacokinetics of a human engineered monoclonal antibody to epithelial cell adhesion molecule. Neoplasia. 2003;5(2):146-154. (Pubitemid 36369010)
18. Munz M, Murr A, Kvesic M, et al. Side-by-side analysis of five clinically tested anti-EpCAM monoclonal antibodies. Cancer Cell Int. 2010;10:44.
19. Oberneder R, Weckermann D, Ebner B, et al. A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients. Eur J Cancer. 2006;42(15):2530-2538. (Pubitemid 44442943)
20. Marschner N, Ruttinger D, Zugmaier G, et al. Phase II study of the human anti-epithelial cell adhesion molecule antibody adecatumumab in prostate cancer patients with increasing serum levels of prostate-specific antigen after radical prostatectomy. Urol Int. 2010;85(4):386-395.
21. Schmidt M, Scheulen ME, Dittrich C, et al. An open-label, randomized phase II study of adecatumumab, a fully human anti-EpCAM antibody, as monotherapy in patients with metastatic breast cancer. Ann Oncol. 2010;21(2):275-282.
22. Shapira S, Shapira A, Starr A, et al. An immunoconjugate of anti-CD24 and Pseudomonas exotoxin selectively kills human colorectal tumors in mice. Gastroenterology. 2011;140(3):935-946.
23. Kovtun YV, Audette CA, Mayo MF, et al. Antibody-maytansinoid conjugates designed to bypass multidrug resistance. Cancer Res. 2010;70(6):2528-2537.
24. Francisco JA, Cerveny CG, Meyer DL, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102(4):1458-1465. (Pubitemid 36988057)
25. Hamblett KJ, Senter PD, Chace DF, et al. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate. Clin Cancer Res. 2004;10(20):7063-7070. (Pubitemid 39383058)
26. Alley SC, Okeley NM, Senter PD. Antibody-drug conjugates: targeted drug delivery for cancer. Curr Opin Chem Biol. 2010;14(4):529-537.
27. Wieland T, Faulstich H. Amatoxins, phallotoxins, phallolysin, and antamanide: the biologically active components of poisonous Amanita mushrooms. CRC Crit Rev Biochem. 1978;5(3):185-260.
28. Wieland T. The toxic peptides from Amanita mushrooms. Int J Pept Protein Res. 1983;22(3):257-276. (Pubitemid 13048506)
29. Wieland T. Peptides of Poisonous Amanita Mushrooms. 1st ed. New York, NY: Springer-Verlag; 1986.
30. Walton JD, Hallen-Adams HE, Luo H. Ribosomal biosynthesis of the cyclic peptide toxins of Amanita mushrooms. Biopolymers. 2010;94(5):659-664.
31. Cochet-Meilhac M, Chambon P. Animal DNA-dependent RNA polymerases. 11. Mechanism of the inhibition of RNA polymerases B by amatoxins. Biochim Biophys Acta. 1974;353(2):160-184.
32. Cochet-Meilhac M, Nuret P, Courvalin JC, Chambon P. Animal DNA-dependent RNA polymerases. 12. Determination of the cellular number of RNA polymerase B molecules. Biochim Biophys Acta. 1974;353(2):185-192.
33. Magdalan J, Ostrowska A, Piotrowska A, et al. Alpha-amanitin induced apoptosis in primary cultured dog hepatocytes. Folia Histochem Cytobiol. 2010;48(1):58-62.
34. Moldenhauer G, Momburg F, Moller P, Schwartz R, Hammerling GJ. Epithelium-specific surface glycoprotein of Mr 34,000 is a widely distributed human carcinoma marker. Br J Cancer. 1987;56(6):714-721. (Pubitemid 18048339)
35. Momburg F, Moldenhauer G, Hammerling GJ, Moller P. Immunohistochemical study of the expression of a Mr 34,000 human epithelium-specific surface glycoprotein in normal and malignant tissues. Cancer Res. 1987;47(11):2883-2891. (Pubitemid 17113431)
36. Kirchner K, Faulstich H. Purification of amatoxin-specific antibodies from rabbit sera by affinity chromatography, their characterization and use in toxicological studies. Toxicon. 1986;24(3):273-283. (Pubitemid 16140098)
37. Salnikov AV, Groth A, Apel A, et al. Targeting of cancer stem cell marker EpCAM by bispecific antibody EpCAMxCD3 inhibits pancreatic carcinoma. J Cell Mol Med. 2009;13(9B):4023-4033.
38. Hussain S, Pluckthun A, Allen TM, Zangemeister-Wittke U. Antitumor activity of an epithelial cell adhesion molecule targeted nanovesicular drug delivery system. Mol Cancer Ther. 2007;6(11):3019-3027. (Pubitemid 350206780)
39. Haisma HJ, Pinedo HM, Rijswijk A, et al. Tumor-specific gene transfer via an adenoviral vector targeted to the pan-carcinoma antigen EpCAM. Gene Ther. 1999;6(8):1469-1474. (Pubitemid 29396735)
40. Heideman DA, Snijders PJ, Craanen ME, et al. Selective gene delivery toward gastric and esophageal adenocarcinoma cells via EpCAM-targeted adenoviral vectors. Cancer Gene Ther. 2001;8(5):342-351. (Pubitemid 32691124)
41. de Graaf M, Boven E, Oosterhoff D, et al. A fully human anti-Ep-CAM scFv-beta-glucuronidase fusion protein for selective chemotherapy with a glucuronide prodrug. Br J Cancer. 2002;86(5):811-818. (Pubitemid 34250827)
42. Schanzer JM, Fichtner I, Baeuerle PA, Kufer P. Antitumor activity of a dual cytokine/single-chain antibody fusion protein for simultaneous delivery of GM-CSF and IL-2 to Ep-CAM expressing tumor cells. J Immunother. 2006;29(5):477-488. (Pubitemid 44403697)
43. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald GC. Engineering and biological characterization of VB6-845, an anti-EpCAM immunotoxin containing a T-cell epitope-depleted variant of the plant toxin bouganin. J Immunother. 2009;32(6):574-584.
44. Patricia MK, Stefan N, Rothschild S, Pluckthun A, Zangemeister-Wittke U. A novel fusion toxin derived from an EpCAM-specific designed ankyrin repeat protein has potent antitumor activity. Clin Cancer Res. 2011;17(1):100-110.
45. MacDonald GC, Rasamoelisolo M, Entwistle J, et al. A phase I clinical study of VB4-845: weekly intratumoral administration of an anti-EpCAM recombinant fusion protein in patients with squamous cell carcinoma of the head and neck. Drug Des Devel Ther. 2009;2:105-114.
46. Oroudjev E, Lopus M, Wilson L, et al. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther. 2010;9(10):2700-2713.
47. Austin CD, Wen X, Gazzard L, Nelson C, Scheller RH, Scales SJ. Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates. Proc Natl Acad Sci USA. 2005;102(50):17987-17992. (Pubitemid 41798489)
48. Faulstich H, Fiume L. Protein conjugates of fungal toxins. Methods Enzymol. 1985;112:225-237. (Pubitemid 15036584)
49. Letschert K, Faulstich H, Keller D, Keppler D. Molecular characterization and inhibition of amanitin uptake into human hepatocytes. Toxicol Sci. 2006;91(1):140-149.
50. Barbanti-Brodano G, Fiume L. Selective killing of macrophages by amanitin-albumin conjugates. Nat New Biol. 1973;243(130):281-283.
51. Barbanti-Brodano G, Derenzini M, Fiume L. Toxic action of a phalloidin-albumin conjugate on cells with a high protein uptake. Nature. 1974;248(443):63-65.
52. Davis MT, Preston JF III. A conjugate of alpha-amanitin and monoclonal immunoglobulin G to Thy 1.2 antigen is selectively toxic to T lymphoma cells. Science. 1981;213(4514):1385-1388. (Pubitemid 12243633)
53. Kowalski M, Entwistle J, Cizeau J, et al. A phase I study of an intravesically administered immunotoxin targeting EpCAM for the treatment of nonmuscle-invasive bladder cancer in BCG-refractory and BCG-intolerant patients. Drug Des Devel Ther. 2010;4:313-320.
54. Marme A, Strauss G, Bastert G, Grischke EM, Moldenhauer G. Intraperitoneal bispecific antibody (HEA125xOKT3) therapy inhibits malignant ascites production in advanced ovarian carcinoma. Int J Cancer. 2002;101(2):183-189. (Pubitemid 34970911)
55. Kosterink JG, McLaughlin PM, Lub-de Hooge MN, et al. Biodistribution studies of epithelial cell adhesion molecule (EpCAM)-directed monoclonal antibodies in the EpCAM-transgenic mouse tumor model. J Immunol. 2007;179(2):1362-1368.